Advertisement

Acta Neurologica Belgica

, Volume 116, Issue 1, pp 57–63 | Cite as

Low vitamin D levels in healthy controls and patients with autoimmune neuromuscular disorders in Greece

  • Elisabeth Chroni
  • Nikolaos Dimisianos
  • Anna Rostedt Punga
Original Article

Abstract

Normal autoimmune function is dependent on adequate levels of activated vitamin D, 25 hydroxy vitamin D [25(OH)D]. A recent study presented deficiency of 25(OH)D levels in Swedish MG patients. We aimed to study 25(OH)D levels in patients with MG and autoimmune polyneuropathies (PNP) at a southern latitude in Greece. Plasma levels of 25(OH)D were analyzed in Greek patients with MG (n = 19), immune-mediated PNP (N = 11) and in 30 Greek healthy age- and sex-matched controls. Ten MG patients received supplementation with vitamin D3. The MG Composite Score (MGC) and MG quality of life assessed disease severity in MG patients, whereas the INCAT Disability Scale assessed clinical features in the PNP patients. MG patients with and without vitamin D3 supplementation had higher 25(OH)D levels (mean 58.8 ± 16.3 and 62.0 ± 22.4 nmol/L, respectively) than PNP patients (mean 42.1 ± 11.5 nmol/L, p = 0.01) and healthy controls (mean 45.7 ± 13.8 nmol/L, p = 0.01). Plasma 25(OH)D levels was lower with age in all groups. There were no correlations between 25(OH)D and disease duration, MGC score, or INCAT score. Vitamin D deficiency was found in all Greek patient groups and healthy controls. Levels of 25(OH)D were higher in MG patients with as well as without vitamin D supplementation compared to healthy controls, whereas CIDP/GBS patients had levels similar to controls.

Keywords

Myasthenia gravis Guillain–Barré syndrome Vitamin D Autoimmune polyneuropathy 

Notes

Acknowledgments

This work was supported by Lars Hiertas memorial foundation and Selanders foundation (ARP).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical and informed consent

All subjects signed written informed consent prior to inclusion into the study. The study protocol was approved by the Ethics Committee of PUH (No of approval: 37 /25-1-2012).

References

  1. 1.
    Yang CY, Leung PS, Adamopoulos IE, Gershwin ME (2013) The implication of vitamin d and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 45:217–226CrossRefPubMedGoogle Scholar
  2. 2.
    Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB et al (2013) Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer fertility, pregnancy, dementia and mortality—a review of recent evidence. Autoimmun Rev. 12:976–989CrossRefPubMedGoogle Scholar
  3. 3.
    Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC et al (2011) Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 70(9):1569–1574PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Lucas RM, Ponsonby AL, Dear K, Valery PC, Pender MP, Taylor BV et al (2011) Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76(6):540–548CrossRefPubMedGoogle Scholar
  5. 5.
    Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B (2007) Vitamin D in rheumatoid arthritis. Autoimmun Rev 7(1):59–64CrossRefPubMedGoogle Scholar
  6. 6.
    Bener A, Alsaied A, Al-Ali M, Al-Kubaisi A, Basha B, Abraham A et al (2009) High prevalence of vitamin D deficiency in type 1 diabetes mellitus and healthy children. Acta Diabetol 46(3):183–189CrossRefPubMedGoogle Scholar
  7. 7.
    Carlander B, Puech-Cathala AM, Jaussent I, Scholz S, Bayard S, Cochen V et al (2011) Low vitamin D in narcolepsy with cataplexy. PLoS One 6(5):e20433PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML (2011) Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001–2006. J Clin Endocrinol Metab 96(12):3838–3845PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Askmark H, Haggard L, Nygren I, Punga AR (2012) Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: a pilot study. Eur J Neurol 19(12):1554–1560CrossRefPubMedGoogle Scholar
  10. 10.
    Elf K, Askmark H, Nygren I, Punga AR (2014) Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies. J Neurol Sci 345(1–2):184–188CrossRefPubMedGoogle Scholar
  11. 11.
    Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009) Vitamin D: an evidence-based review. J Am Board Fam Med 22(6):698–706CrossRefPubMedGoogle Scholar
  12. 12.
    Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16–23CrossRefPubMedGoogle Scholar
  13. 13.
    Burns TM, Conaway M, Sanders DB (2010) The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74(18):1434–1440PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Padua L, Evoli A, Aprile I, Caliandro P, Batocchi AP, Punzi C et al (2002) Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire. Neurol Sci 23(2):59–68CrossRefPubMedGoogle Scholar
  15. 15.
    Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG (2001) Diagnostic and classification criteria for the Guillain–Barre syndrome. Eur Neurol 45(3):133–139CrossRefPubMedGoogle Scholar
  16. 16.
    Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves M et al (2009) Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 277(1–2):1–8CrossRefPubMedGoogle Scholar
  17. 17.
    Merkies IS, Schmitz PI (2006) Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry 77(8):970–972PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Askmark H, Haggard L, Nygren I, Punga AR (2012) Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: a pilot study. Eur J Neurol 19:1554–1560CrossRefPubMedGoogle Scholar
  19. 19.
    Lapatsanis D, Moulas A, Cholevas V, Soukakos P, Papadopoulou ZL, Challa A (2005) Vitamin D: a necessity for children and adolescents in Greece. Calcif Tissue Int 77(6):348–355CrossRefPubMedGoogle Scholar
  20. 20.
    Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–281CrossRefPubMedGoogle Scholar
  21. 21.
    Ferder M, Inserra F, Manucha W, Ferder L (2013) The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system. Am J Physiol Cell Physiol 304(11):C1027–C1039PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    McKenna MJ (1992) Differences in vitamin D status between countries in young adults and the elderly. Am J Med 93(1):69–77CrossRefPubMedGoogle Scholar
  23. 23.
    Sedrani SH (1984) Low 25-hydroxyvitamin D and normal serum calcium concentrations in Saudi Arabia: riyadh region. Ann Nutr Metab 28(3):181–185CrossRefPubMedGoogle Scholar
  24. 24.
    Marwaha RK, Tandon N, Reddy DR, Aggarwal R, Singh R, Sawhney RC et al (2005) Vitamin D and bone mineral density status of healthy schoolchildren in northern India. Am J Clin Nutr 82(2):477–482PubMedGoogle Scholar
  25. 25.
    Ekiz O, Balta I, Sen BB, Dikilitas MC, Ozuguz P, Rifaioglu EN (2013) Vitamin D status in patients with rosacea. Cutan Ocul Toxicol 33:60–62CrossRefPubMedGoogle Scholar
  26. 26.
    Becker W, Darnerud PO, Petersson-Grawe K (2007) Fiskkonsumtion-risk och nytta. National Food Adm, UppsalaGoogle Scholar
  27. 27.
    Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT et al (2005) Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90(6):3215–3224CrossRefPubMedGoogle Scholar
  28. 28.
    Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, Maalouf G et al (2006) The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 260(3):245–254CrossRefPubMedGoogle Scholar
  29. 29.
    Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W (2004) Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 19(2):265–269CrossRefPubMedGoogle Scholar
  30. 30.
    Aloia JF (2011) Clinical Review: the 2011 report on dietary reference intake for vitamin D: where do we go from here? J Clin Endocrinol Metab 96(10):2987–2996CrossRefPubMedGoogle Scholar
  31. 31.
    Heaney RP, Holick MF (2011) Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res 26(3):455–457CrossRefPubMedGoogle Scholar
  32. 32.
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930CrossRefPubMedGoogle Scholar
  33. 33.
    Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, Krueger D et al (2011) Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. J Clin Endocrinol Metab 96(4):981–988PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Belgian Neurological Society 2015

Authors and Affiliations

  • Elisabeth Chroni
    • 1
  • Nikolaos Dimisianos
    • 1
  • Anna Rostedt Punga
    • 2
  1. 1.Department of Neurology, School of MedicineUniversity of PatrasPatrasGreece
  2. 2.Department of Clinical Neurophysiology, Institute of Neuroscience, Uppsala University HospitalUppsala UniversityUppsalaSweden

Personalised recommendations